Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
Clarke E, Jarvis CI, Goncalves MB, Kalindjian SB, Adams DR, Brown JT, Shiers JJ, Taddei DMA, Ravier E, Barlow S, Miller I, Smith V, Borthwick AD, Corcoran JPT. Clarke E, et al. Among authors: kalindjian sb. Bioorg Med Chem. 2018 Feb 15;26(4):798-814. doi: 10.1016/j.bmc.2017.12.015. Epub 2017 Dec 9. Bioorg Med Chem. 2018. PMID: 29288071 Free PMC article.
Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
Low CM, Buck IM, Cooke T, Cushnir JR, Kalindjian SB, Kotecha A, Pether MJ, Shankley NP, Vinter JG, Wright L. Low CM, et al. Among authors: kalindjian sb. J Med Chem. 2005 Nov 3;48(22):6790-802. doi: 10.1021/jm049069y. J Med Chem. 2005. PMID: 16250638
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
Buck IM, Black JW, Cooke T, Dunstone DJ, Gaffen JD, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Low CM, McDonald IM, Pether MJ, Roberts SP, Shankley NP, Shaxted ME, Steel KI, Sykes DA, Tozer MJ, Watt GF, Walker MK, Wright L, Wright PT. Buck IM, et al. Among authors: kalindjian sb. J Med Chem. 2005 Nov 3;48(22):6803-12. doi: 10.1021/jm0490686. J Med Chem. 2005. PMID: 16250639
Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
McDonald IM, Black JW, Buck IM, Dunstone DJ, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Pether MJ, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Walker MK, Watt GF, Wright L, Wright PT, Xun W. McDonald IM, et al. Among authors: kalindjian sb. J Med Chem. 2007 Jun 28;50(13):3101-12. doi: 10.1021/jm070139l. Epub 2007 May 31. J Med Chem. 2007. PMID: 17536796
Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.
McDonald IM, Austin C, Buck IM, Dunstone DJ, Gaffen J, Griffin E, Harper EA, Hull RA, Kalindjian SB, Linney ID, Low CM, Patel D, Pether MJ, Raynor M, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Wright PT, Xun W. McDonald IM, et al. Among authors: kalindjian sb. J Med Chem. 2007 Oct 4;50(20):4789-92. doi: 10.1021/jm0707626. Epub 2007 Sep 12. J Med Chem. 2007. PMID: 17850061
33 results